bioRxiv · 10.1101/2021.12.16.472927
Interferon-gamma mediates skeletal muscle lesions through JAK/STAT pathway activation in inclusion body myositis
Abstract
Dysimmune and Inflammatory Myopathies (DIMs) are acquired idiopathic myopathy associated with immune response dysregulation. Inclusion Body Myositis (IBM), the most common DIMs, is characterized by endomysial infiltrates of cytotoxic T lymphocytes CD8, muscle type II-interferon (IFN{gamma}) signature, and by the lack of response to immunomodulatory therapies. We showed that IBM was pathologically characterized by the presence of chronic degenerative myopathic features including myofiber atrophy, fibrosis, adipose involution, and the altered functions of skeletal muscle stem cells. Here, we demonstrated that protracted systemic exposure to IFN{gamma} delayed muscle regeneration and led to IBM-like muscular degenerative changes in mice. In vitro, IFN{gamma} treatment inhibited the activation, proliferation, migration, differentiation, and fusion of myogenic progenitor cells and promoted their senescence through JAK-STAT-dependent activation. Finally, JAK-STAT inhibitor, ruxolitinib abrogated the deleterious effects of IFN{gamma} on muscle regeneration, suggesting that the JAK-STAT pathway could represent a new therapeutic target for IBM.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Hou, C., Periou, B., Gervais, M., Berthier, J., Baba-Amer, Y., Souvannanorath, S., Malfatti, E., Relaix, F., bencze, M., Authier, F. J.. 2021-12-16. Interferon-gamma mediates skeletal muscle lesions through JAK/STAT pathway activation in inclusion body myositis. https://doi.org/10.1101/2021.12.16.472927
Cite the original work for its findings. Save a collection to share your selection of sources.